https://www.us.argenx.com/2026-03-26T18:52:51.068Z1.0https://www.us.argenx.com/publications2024-06-19T09:51:31.36Z1.0https://www.us.argenx.com/externally-sponsored-research_msm_moved2024-06-27T01:51:05.819Z1.0https://www.us.argenx.com/products2025-03-28T16:55:16.959Z1.0https://www.us.argenx.com/patients2026-02-13T01:17:37.392Z1.0https://www.us.argenx.com/patients/myasthenia-gravis2026-02-12T16:31:04.548Z1.0https://www.us.argenx.com/patients/immune-thrombocytopenia2026-02-12T16:45:07.9Z1.0https://www.us.argenx.com/patients/clinical-trials2026-03-05T02:46:12.636Z1.0https://www.us.argenx.com/patients/clinical-trials/post-trial-access2024-10-25T12:31:30.646Z1.0https://www.us.argenx.com/patients/chronic-inflammatory-demyelinating-polyneuropathy2026-02-12T16:56:43.564Z1.0https://www.us.argenx.com/patients/pemphigus-vulgaris2024-08-01T12:04:12.09Z1.0https://www.us.argenx.com/patients/severe-autoimmunity2024-08-01T12:04:14.811Z1.0https://www.us.argenx.com/patients/monica-seles--from-champion-to-advocate2025-08-22T02:06:31.374Z1.0https://www.us.argenx.com/innovation2026-02-22T17:23:58.3Z1.0https://www.us.argenx.com/investors2024-09-04T10:43:52.179Z1.0https://www.us.argenx.com/investors/stock-information2024-09-09T09:59:10.702Z1.0https://www.us.argenx.com/investors/sec-filings2024-08-01T07:40:31.952Z1.0https://www.us.argenx.com/investors/governance2024-08-05T12:51:18.158Z1.0https://www.us.argenx.com/investors/governance/board-of-directors2025-12-29T16:55:34.903Z1.0https://www.us.argenx.com/investors/governance/board-of-directors/board-committees2025-12-08T14:59:40.08Z1.0https://www.us.argenx.com/investors/governance/legal-structure2025-08-06T18:14:20.552Z1.0https://www.us.argenx.com/investors/governance/executive-management2025-09-22T15:36:34.602Z1.0https://www.us.argenx.com/investors/governance/risk-control-systems2025-07-30T19:53:21.03Z1.0https://www.us.argenx.com/investors/governance/rules-codes-compliance2025-10-08T07:21:58.471Z1.0https://www.us.argenx.com/investors/governance/remuneration-policy2026-01-05T20:09:11.37Z1.0https://www.us.argenx.com/investors/analyst-coverage2026-02-18T19:18:14.884Z1.0https://www.us.argenx.com/investors/shareholder-meetings2025-05-02T02:36:42.581Z1.0https://www.us.argenx.com/investors/events-presentations2026-03-03T22:48:07.574Z1.0https://www.us.argenx.com/investors/afm-filings2024-09-05T13:39:42.479Z1.0https://www.us.argenx.com/investors/financial-reports2026-03-18T19:36:16.565Z1.0https://www.us.argenx.com/investors/events2024-08-01T07:25:47.019Z1.0https://www.us.argenx.com/investors/corporate-governance2024-09-11T07:38:04.371Z1.0https://www.us.argenx.com/about2026-03-11T06:58:58.665Z1.0https://www.us.argenx.com/newsroom2026-03-20T20:04:52.206Z1.0https://www.us.argenx.com/newsroom/argenx-stories2024-09-17T17:01:39.509Z1.0https://www.us.argenx.com/newsroom/argenx-stories/employee-stories2024-08-06T10:08:32.017Z1.0https://www.us.argenx.com/newsroom/argenx-stories/employee-stories/jenna-casey-program-leader-launch-excellence-boston2024-08-07T08:13:51.46Z1.0https://www.us.argenx.com/newsroom/argenx-stories/employee-stories/rene-bigirimanaa-sientist-discovery-department-ghent2024-08-06T14:32:00.121Z1.0https://www.us.argenx.com/newsroom/argenx-stories/employee-stories/subir-puri-director-medical-research-liaisons-boston2024-07-29T10:14:11.862Z1.0https://www.us.argenx.com/newsroom/argenx-stories/our-story2024-08-16T05:39:28.676Z1.0https://www.us.argenx.com/newsroom/argenx-stories/our-story/building-blocks-of-a-biotech2025-08-05T06:50:31.975Z1.0https://www.us.argenx.com/newsroom/argenx-stories/our-story/founding-of-argenx2025-08-05T06:51:12.096Z1.0https://www.us.argenx.com/newsroom/argenx-stories/our-story/together-we-discover2025-08-05T09:31:39.64Z1.0https://www.us.argenx.com/newsroom/argenx-stories/immunology-innovation2024-08-06T08:00:13.15Z1.0https://www.us.argenx.com/newsroom/argenx-stories/immunology-innovation/what-fcrn-and-could-blocking-fcrn-redefine-treatment-dozens-autoimmune-diseases2025-08-06T03:59:50.858Z1.0https://www.us.argenx.com/newsroom/argenx-stories/immunology-innovation/iip-spotlight-working-together-tackle-asthma2025-08-05T09:53:15.436Z1.0https://www.us.argenx.com/newsroom/argenx-stories/pipeline2024-08-06T08:12:43.453Z1.0https://www.us.argenx.com/newsroom/argenx-stories/pipeline/when-hans-met-sally-our-fcrn-antibody-development2025-08-05T09:56:54.686Z1.0https://www.us.argenx.com/newsroom/argenx-stories/culture2024-08-01T12:27:39.371Z1.0https://www.us.argenx.com/newsroom/argenx-stories/culture/discovering-immunology-breakthroughs-its-marathon-not-sprint2025-08-05T10:02:08.063Z1.0https://www.us.argenx.com/newsroom/argenx-stories/patient-stories2024-09-18T11:42:39.702Z1.0https://www.us.argenx.com/newsroom/argenx-stories/patient-stories/life-with-myasthenia-gravis-first-time-in-crisis2025-08-05T10:05:26.924Z1.0https://www.us.argenx.com/newsroom/argenx-stories/patient-stories/one-mom-s-journey-with-myasthenia-gravis2025-08-05T10:08:19.219Z1.0https://www.us.argenx.com/newsroom/argenx-stories/patient-stories/the-loneliness-of-life-with-myasthenia-gravis2025-08-05T10:11:50.682Z1.0https://www.us.argenx.com/newsroom/argenx-stories/patient-stories/finding-support-in-the-myasthenia-gravis-community2025-08-05T10:14:13.816Z1.0https://www.us.argenx.com/newsroom/argenx-stories/patient-stories/managing-the-toll-of-myasthenia-gravis-it-takes-a-team2025-08-05T10:16:18.884Z1.0https://www.us.argenx.com/newsroom/argenx-stories/patient-stories/myasthenia-gravis-diagnosis-a-six-year-journey2025-08-05T10:19:13.165Z1.0https://www.us.argenx.com/newsroom/argenx-stories/patient-stories/the-long-road-to-a-myasthenia-gravis-diagnosis2025-08-05T10:21:16.276Z1.0https://www.us.argenx.com/newsroom/argenx-stories/patient-stories/when-career-goals-collide-with-myasthenia-gravis2025-08-05T10:23:07.853Z1.0https://www.us.argenx.com/newsroom/argenx-stories/patient-stories/meet-jerry-williams-connecting-and-advocating-people-polymyositis2025-08-05T10:25:34.816Z1.0https://www.us.argenx.com/news2024-07-10T10:38:54.536Z1.0https://www.us.argenx.com/news/20092024-05-07T18:54:21.085Z1.0https://www.us.argenx.com/news/2009/argen-x-opens-new-rd-facility-flanders2024-05-07T18:54:21.257Z1.0https://www.us.argenx.com/news/2009/argen-x-raises-eu95-million-put-simple-antibodytm-platform-work2024-05-07T18:54:21.424Z1.0https://www.us.argenx.com/news/20102024-05-07T18:54:21.549Z1.0https://www.us.argenx.com/news/2010/argen-x-appoints-dr-debbie-allen-senior-director-business-development2024-05-07T18:54:21.689Z1.0https://www.us.argenx.com/news/2010/argen-x-awarded-eu15-million-iwt-grant-accelerate-pre-clinical-antibody-development2024-05-07T18:54:21.844Z1.0https://www.us.argenx.com/news/2010/argen-x-granted-broad-patent-covering-its-unique-simple-antibodytm-platform2024-05-07T18:54:22.215Z1.0https://www.us.argenx.com/news/2010/argen-x-concludes-eur-125-million-series-financing-round2024-05-07T18:54:21.995Z1.0https://www.us.argenx.com/news/2010/argen-x-simple-antibodytm-platform-set-transform-therapeutic-antibody-discovery-development2024-05-07T18:54:22.363Z1.0https://www.us.argenx.com/news/20112024-05-07T18:54:22.479Z1.0https://www.us.argenx.com/news/2011/argen-x-raises-eur-275-million-usd-37-million-oversubscribed-series-b-round2024-05-07T18:54:23.234Z1.0https://www.us.argenx.com/news/2011/argen-x-awarded-eu13-million-iwt-grant-advance-proprietary-simple-antibodytm-platform2024-05-07T18:54:22.736Z1.0https://www.us.argenx.com/news/2011/argen-x-presents-significant-progress-biopharm-america-20112024-05-07T18:54:23.085Z1.0https://www.us.argenx.com/news/2011/argen-x-announces-non-exclusive-license-biowa-potelligentr-technology2024-05-07T18:54:22.595Z1.0https://www.us.argenx.com/news/2011/argen-x-initiates-second-pre-clinical-development-program-under-18-months-start-operations2024-05-07T18:54:22.916Z1.0https://www.us.argenx.com/news/2011/argen-x-signs-discovery-and-development-alliance-lilly2024-05-07T18:54:23.381Z1.0https://www.us.argenx.com/news/20122024-05-07T18:54:23.486Z1.0https://www.us.argenx.com/news/2012/argen-x-announces-grant-broad-us-patent-covering-its-simple-antibodytm-platform2024-05-07T18:54:23.747Z1.0https://www.us.argenx.com/news/2012/argen-x-reveals-target-and-unique-mechanism-action-its-most-advanced-preclinical-antibody-pegs2024-05-07T18:54:24.685Z1.0https://www.us.argenx.com/news/2012/argen-x-appoints-dr-david-l-lacey-its-supervisory-board2024-05-07T18:54:24.097Z1.0https://www.us.argenx.com/news/2012/ruiyi-formerly-anaphore-and-argen-x-announce-exclusive-worldwide-license-agreement-argx-1092024-05-07T18:54:24.992Z1.0https://www.us.argenx.com/news/2012/cambridge-healthtech-associatestm-announces-argen-x-inaugural-signature-awardtm-winner2024-05-07T18:54:24.83Z1.0https://www.us.argenx.com/news/2012/argen-x-granted-first-us-patent-covering-its-unique-nhancetm-technology2024-05-07T18:54:24.384Z1.0https://www.us.argenx.com/news/2012/argen-x-launches-nhancetm-technology-generate-better-human-antibody-therapies2024-05-07T18:54:24.534Z1.0https://www.us.argenx.com/news/2012/argen-x-appoints-alain-thibault-chief-medical-officer-and-koos-rasser-ip-counsel2024-05-07T18:54:23.919Z1.0https://www.us.argenx.com/news/2012/argen-x-advances-third-therapeutic-antibody-program-preclinical-development2024-05-07T18:54:23.596Z1.0https://www.us.argenx.com/news/2012/argen-x-enters-therapeutic-antibody-alliance-shire2024-05-07T18:54:24.238Z1.0https://www.us.argenx.com/news/20132024-05-07T18:54:25.105Z1.0https://www.us.argenx.com/news/2013/argx-110-novel-anti-cd70-antibody-meets-translational-development-goals-dose-escalation-part2024-05-07T18:54:26.745Z1.0https://www.us.argenx.com/news/2013/argen-x-raises-eur-5-million-pmv-extension-eur-325-million-series-b2024-05-07T18:54:26.446Z1.0https://www.us.argenx.com/news/2013/argen-x-and-de-duve-instituteucl-collaborate-novel-immunomodulation-therapy-cancer2024-05-07T18:54:25.212Z1.0https://www.us.argenx.com/news/2013/argen-x-reaches-milestone-simple-antibodytm-research-and-product-development-collaboration2024-05-07T18:54:26.599Z1.0https://www.us.argenx.com/news/2013/argen-x-initiates-phase-ib-study-argx-111-cancer2024-05-07T18:54:26.126Z1.0https://www.us.argenx.com/news/2013/argen-x-identifies-potent-antibody-antagonists-against-complex-chronic-pain-target-nav172024-05-07T18:54:25.817Z1.0https://www.us.argenx.com/news/2013/argen-x-grants-license-its-nhancetm-antibody-half-life-extension-technology2024-05-07T18:54:25.672Z1.0https://www.us.argenx.com/news/2013/argen-x-present-upcoming-ninth-annual-pegs-20132024-05-07T18:54:26.295Z1.0https://www.us.argenx.com/news/2013/argen-x-announces-preclinical-development-argx-112-dermatology2024-05-07T18:54:25.356Z1.0https://www.us.argenx.com/news/2013/argen-x-expands-its-therapeutic-antibody-alliance-shire2024-05-07T18:54:25.526Z1.0https://www.us.argenx.com/news/2013/argen-x-initiates-phase-ib-study-argx-110-cancer2024-05-07T18:54:25.959Z1.0https://www.us.argenx.com/news/20142024-05-07T18:54:26.87Z1.0https://www.us.argenx.com/news/2014/argen-x-announces-advancement-therapeutic-antibody-alliance-shire2024-05-07T18:54:27.275Z1.0https://www.us.argenx.com/news/2014/argen-x-reports-preclinical-data-argx-110-chronic-myelogenous-leukemia-model2024-05-07T18:54:29.951Z1.0https://www.us.argenx.com/news/2014/argen-x-third-quarter-business-update2024-05-07T18:54:30.404Z1.0https://www.us.argenx.com/news/2014/argen-x-initiates-clinical-efficacy-evaluation-argx-110-patients-relapsedrefractory-cd702024-05-07T18:54:28.874Z1.0https://www.us.argenx.com/news/2014/argen-x-submits-investigational-new-drug-application-evaluate-argx-110-waldenstroms2024-05-07T18:54:30.26Z1.0https://www.us.argenx.com/news/2014/argen-x-completes-recruitment-first-cohort-15-patients-cd70-positive-hematological2024-05-07T18:54:28.29Z1.0https://www.us.argenx.com/news/2014/argen-x-completes-recruitment-first-cohort-15-patients-cd70-positive-solid-tumors-its-phase-1b2024-05-07T18:54:28.435Z1.0https://www.us.argenx.com/news/2014/argen-x-core-patents-protecting-lead-clinical-candidates-argx-110-and-argx-111-receive2024-05-07T18:54:28.584Z1.0https://www.us.argenx.com/news/2014/argen-x-appoints-petercam-nv-liquidity-provider-facilitate-trading-euronext-brussels2024-05-07T18:54:27.998Z1.0https://www.us.argenx.com/news/2014/argen-x-business-update-and-first-half-2014-results2024-05-07T18:54:28.143Z1.0https://www.us.argenx.com/news/2014/argen-x-announces-positive-preclinical-results-argx-1132024-05-07T18:54:27.722Z1.0https://www.us.argenx.com/news/2014/argen-x-raises-additional-eu18-million-exercise-over-allotment-option-and-announces-end2024-05-07T18:54:29.502Z1.0https://www.us.argenx.com/news/2014/argen-x-present-wedbush-2014-life-sciences-management-access-conference2024-05-07T18:54:29.36Z1.0https://www.us.argenx.com/news/2014/argen-x-raises-eu40-million-successful-initial-public-offering-euronext-brussels2024-05-07T18:54:29.642Z1.0https://www.us.argenx.com/news/2014/argen-x-launches-initial-public-offering-euronext-brussels2024-05-07T18:54:29.026Z1.0https://www.us.argenx.com/news/2014/argen-x-announces-intention-launch-initial-public-offering-euronext-brussels2024-05-07T18:54:27.575Z1.0https://www.us.argenx.com/news/2014/argen-x-enters-long-term-strategic-alliance-shire-pharmaceuticals-therapeutic-antibodies2024-05-07T18:54:28.732Z1.0https://www.us.argenx.com/news/2014/argen-x-present-results-phase-1-study-argx-110-novel-anti-cd70-antibody-patients-advanced2024-05-07T18:54:29.18Z1.0https://www.us.argenx.com/news/2014/argen-x-announces-collaboration-bayer-discover-and-develop-therapeutic-antibody-candidates2024-05-07T18:54:27.418Z1.0https://www.us.argenx.com/news/2014/argen-x-appoints-dr-werner-lanthaler-its-supervisory-board2024-05-07T18:54:27.863Z1.0https://www.us.argenx.com/news/2014/argen-x-uses-its-simple-antibodytm-platform-identify-four-hotspots-met-targets-its-therapeutic2024-05-07T18:54:30.558Z1.0https://www.us.argenx.com/news/2014/argen-x-receives-two-preclinical-milestone-payments-under-collaboration-shire2024-05-07T18:54:29.792Z1.0https://www.us.argenx.com/news/2014/argen-x-starts-phase-ib-expansion-cohorts-argx-110-novel-anti-cd70-antibody-cancer-patients2024-05-07T18:54:30.118Z1.0https://www.us.argenx.com/news/2014/argen-x-advances-argx-113-preclinical-development-autoimmune-disorders2024-05-07T18:54:26.984Z1.0https://www.us.argenx.com/news/20152024-05-07T18:54:30.668Z1.0https://www.us.argenx.com/news/2015/argen-x-announces-half-year-results-20152024-05-07T18:54:31.196Z1.0https://www.us.argenx.com/news/2015/argen-x-host-conference-call-webcast-report-half-year-results-26-august-20152024-05-07T18:54:32.362Z1.0https://www.us.argenx.com/news/2015/argen-x-partner-ruiyi-inc-announces-first-human-dosing-gerilimzumab-novel-simple-antibodytm2024-05-07T18:54:32.947Z1.0https://www.us.argenx.com/news/2015/argen-x-present-wedbush-pacgrow-healthcare-conference2024-05-07T18:54:33.409Z1.0https://www.us.argenx.com/news/2015/argen-x-and-university-bern-enter-license-agreement-develop-argx-110-based-combination2024-05-07T18:54:30.914Z1.0https://www.us.argenx.com/news/2015/change-board-directors2024-05-07T18:54:34.387Z1.0https://www.us.argenx.com/news/2015/preliminary-phase-i-results-argx-110-patients-t-cell-lymphomas-presented-icml2024-05-07T18:54:34.666Z1.0https://www.us.argenx.com/news/2015/argen-x-present-jefferies-2015-global-healthcare-conference-tuesday-2-june-800am-edt2024-05-07T18:54:33.259Z1.0https://www.us.argenx.com/news/2015/argen-x-presents-preliminary-efficacy-and-expanded-safety-data-phase-i-trial-argx-111-asco2024-05-07T18:54:33.701Z1.0https://www.us.argenx.com/news/2015/argen-x-and-leo-pharma-enter-alliance-develop-antibody-based-treatments-skin-conditions2024-05-07T18:54:30.771Z1.0https://www.us.argenx.com/news/2015/argen-x-awarded-eu15-million-iwt-grant-advance-application-nhancer-fc-modifications2024-05-07T18:54:31.651Z1.0https://www.us.argenx.com/news/2015/argen-x-first-quarter-2015-financial-results-and-business-update2024-05-07T18:54:32.079Z1.0https://www.us.argenx.com/news/2015/argen-x-announces-results-annual-general-meeting-20152024-05-07T18:54:31.51Z1.0https://www.us.argenx.com/news/2015/argen-x-announces-publication-therapeutic-potential-argx-115-cancer-immunotherapy2024-05-07T18:54:31.36Z1.0https://www.us.argenx.com/news/2015/argen-x-nv-announces-changes-board-directors2024-05-07T18:54:32.659Z1.0https://www.us.argenx.com/news/2015/argen-x-opens-expansion-cohort-phase-1b-study-argx-111-patients-met-amplified-cancers2024-05-07T18:54:32.8Z1.0https://www.us.argenx.com/news/2015/argen-x-announces-annual-general-meeting-shareholders-13-may-20152024-05-07T18:54:31.055Z1.0https://www.us.argenx.com/news/2015/argen-x-reports-fourth-quarter-business-update-and-full-year-2014-financial-results2024-05-07T18:54:33.841Z1.0https://www.us.argenx.com/news/2015/argen-x-present-22nd-annual-biocentury-future-leaders-biotech-industry-conference2024-05-07T18:54:33.093Z1.0https://www.us.argenx.com/news/2015/argen-x-host-conference-call-webcast-report-fourth-quarter-business-update-and-full-year-20142024-05-07T18:54:32.217Z1.0https://www.us.argenx.com/news/2015/argen-x-expands-preclinical-pipeline-argx-115-novel-simple-antibodytm-cancer-immunotherapy2024-05-07T18:54:31.938Z1.0https://www.us.argenx.com/news/2015/argen-x-presents-argx-111-targeted-anticancer-therapies2024-05-07T18:54:33.56Z1.0https://www.us.argenx.com/news/2015/lonza-and-argen-x-announce-multi-product-gs-xceedtm-license-agreement-therapeutic-antibodies2024-05-07T18:54:34.527Z1.0https://www.us.argenx.com/news/2015/argen-x-launches-innovative-access-program2024-05-07T18:54:32.513Z1.0https://www.us.argenx.com/news/2015/argen-x-completes-first-dosing-argx-113-severe-autoimmune-disorders2024-05-07T18:54:31.793Z1.0https://www.us.argenx.com/news/2015/argenx-present-key-investor-conferences2024-05-07T18:54:34.115Z1.0https://www.us.argenx.com/news/2015/argenx-reports-third-quarter-2015-financial-results-and-provides-business-update2024-05-07T18:54:34.25Z1.0https://www.us.argenx.com/news/2015/argenx-host-workshop-and-webcast-announcing-topline-clinical-tcl-data-and-preclinical-aml-data2024-05-07T18:54:33.979Z1.0https://www.us.argenx.com/news/20162024-05-07T18:54:34.87Z1.0https://www.us.argenx.com/news/2016/argenx-announces-initial-results-phase-1-single-ascending-dose-study-argx-113-healthy2024-05-07T18:54:37.41Z1.0https://www.us.argenx.com/news/2016/argenx-announces-eu-16-m-investment-us-funds-advised-subsidiaries-federated-investors2024-05-07T18:54:36.785Z1.0https://www.us.argenx.com/news/2016/argenx-successfully-closes-transaction-us-funds-advised-subsidiaries-federated-investors2024-05-07T18:54:41.313Z1.0https://www.us.argenx.com/news/2016/argenx-receives-milestone-payment-leo-pharma-collaboration2024-05-07T18:54:40.355Z1.0https://www.us.argenx.com/news/2016/argenx-present-leerink-partners-5th-annual-global-healthcare-conference2024-05-07T18:54:39.591Z1.0https://www.us.argenx.com/news/2016/argenx-opens-clinical-trial-sites-south-korea-argx-111-program2024-05-07T18:54:39.401Z1.0https://www.us.argenx.com/news/2016/argenx-home-member-state-selection2024-05-07T18:54:38.589Z1.0https://www.us.argenx.com/news/2016/argenx-host-conference-call-webcast-report-fourth-quarter-business-update-and-full-year-20152024-05-07T18:54:38.749Z1.0https://www.us.argenx.com/news/2016/argenx-reports-fourth-quarter-business-update-and-full-year-2015-financial-results2024-05-07T18:54:40.694Z1.0https://www.us.argenx.com/news/2016/argenxs-partner-bird-rock-bio-demonstrates-potential-gerilimzumab-novel-simple-antibodytm2024-05-07T18:54:41.491Z1.0https://www.us.argenx.com/news/2016/argenx-announces-annual-general-meeting-shareholders-28-april-20162024-05-07T18:54:35.567Z1.0https://www.us.argenx.com/news/2016/argenx-and-abbvie-collaborate-argx-115-against-novel-immuno-oncology-target2024-05-07T18:54:35.182Z1.0https://www.us.argenx.com/news/2016/argenx-announces-results-annual-general-meeting-20162024-05-07T18:54:38.406Z1.0https://www.us.argenx.com/news/2016/argenx-reports-first-quarter-2016-financial-results-and-provides-business-update2024-05-07T18:54:40.503Z1.0https://www.us.argenx.com/news/2016/argenx-announces-private-placement-2703000-new-shares-aggregate-amount-eu30-million2024-05-07T18:54:37.971Z1.0https://www.us.argenx.com/news/2016/argenx-announces-efficacy-and-expanded-safety-data-phase-1-trial-argx-1112024-05-07T18:54:36.168Z1.0https://www.us.argenx.com/news/2016/argenx-successfully-closes-eu30-million-private-placement2024-05-07T18:54:41.17Z1.0https://www.us.argenx.com/news/2016/argenx-announces-presentation-updated-argx-110-phase-1-data-tcl-eha-20162024-05-07T18:54:37.692Z1.0https://www.us.argenx.com/news/2016/argenx-announces-initial-results-phase-1-multiple-ascending-dose-mad-study-argx-113-healthy2024-05-07T18:54:37.176Z1.0https://www.us.argenx.com/news/2016/argenx-host-conference-call-webcast-report-second-quarter-2016-business-update-and-half-year2024-05-07T18:54:38.925Z1.0https://www.us.argenx.com/news/2016/argenx-present-wedbush-pacgrow-healthcare-conference2024-05-07T18:54:39.915Z1.0https://www.us.argenx.com/news/2016/argenx-reports-second-quarter-business-update-and-half-year-2016-financial-results2024-05-07T18:54:40.848Z1.0https://www.us.argenx.com/news/2016/argenx-host-inaugural-rd-day-and-webcast-september-22-20162024-05-07T18:54:39.076Z1.0https://www.us.argenx.com/news/2016/argenx-provides-update-lead-programs-auto-immune-disease-and-oncology-rd-day-new-york2024-05-07T18:54:40.214Z1.0https://www.us.argenx.com/news/2016/frost-sullivan-applauds-argenx-enhancing-therapeutic-qualities-human-antibodies-its2024-05-07T18:54:41.669Z1.0https://www.us.argenx.com/news/2016/argenx-reports-third-quarter-2016-financial-results-and-provides-business-update2024-05-07T18:54:40.996Z1.0https://www.us.argenx.com/news/2016/argenx-present-upcoming-investor-conferences2024-05-07T18:54:39.76Z1.0https://www.us.argenx.com/news/2016/argenx-provide-updates-argx-113-and-argx-110-during-american-society-hematology-annual-meeting2024-05-07T18:54:40.07Z1.0https://www.us.argenx.com/news/2016/argenx-launches-phase-iii-study-argx-110-combination-azacitidine-newly-diagnosed-aml-patients2024-05-07T18:54:39.223Z1.0https://www.us.argenx.com/news/2016/argenx-announces-publication-seminal-data-supporting-therapeutic-potential-argx-110-acute2024-05-07T18:54:38.191Z1.0https://www.us.argenx.com/news/20172024-05-07T18:54:41.78Z1.0https://www.us.argenx.com/news/2017/argenx-launches-phase-ii-proof-concept-study-argx-113-treatment-myasthenia-gravis2024-05-07T18:54:46.035Z1.0https://www.us.argenx.com/news/2017/argenx-present-leerink-partners-6th-annual-global-healthcare-conference2024-05-07T18:54:46.798Z1.0https://www.us.argenx.com/news/2017/argenx-announces-extension-therapeutic-antibody-alliance-shire2024-05-07T18:54:42.479Z1.0https://www.us.argenx.com/news/2017/argenx-present-cowen-co-37th-annual-healthcare-conference2024-05-07T18:54:46.454Z1.0https://www.us.argenx.com/news/2017/argenx-announces-intention-conduct-registered-public-offering-united-states2024-05-07T18:54:42.924Z1.0https://www.us.argenx.com/news/2017/argenx-announces-staten-biotech-exercised-its-option-develop-therapeutic-simple-antibodytm2024-05-07T18:54:44.917Z1.0https://www.us.argenx.com/news/2017/argenx-host-conference-call-webcast-report-fourth-quarter-business-update-and-full-year-20162024-05-07T18:54:45.214Z1.0https://www.us.argenx.com/news/2017/argenx-reports-fourth-quarter-business-update-and-full-year-2016-financial-results2024-05-07T18:54:48.871Z1.0https://www.us.argenx.com/news/2017/argenx-announces-annual-general-meeting-shareholders-26-april-20172024-05-07T18:54:41.888Z1.0https://www.us.argenx.com/news/2017/argenx-announces-collaboration-broteio-pharma-develop-therapeutic-antibody-severe-autoimmune2024-05-07T18:54:42.331Z1.0https://www.us.argenx.com/news/2017/argenx-announces-first-patient-dosed-phase-ii-proof-concept-study-argx-113-treatment-primary2024-05-07T18:54:42.626Z1.0https://www.us.argenx.com/news/2017/argenx-launches-phase-ii-study-argx-110-monotherapy-relapsedrefractory-ctcl-patients2024-05-07T18:54:46.211Z1.0https://www.us.argenx.com/news/2017/argenx-receives-first-preclinical-milestone-payment-abbvie-collaboration2024-05-07T18:54:48.391Z1.0https://www.us.argenx.com/news/2017/argenx-files-registration-statement-proposed-public-offering-united-states2024-05-07T18:54:45.065Z1.0https://www.us.argenx.com/news/2017/argenx-announces-results-annual-general-meeting-20172024-05-07T18:54:44.17Z1.0https://www.us.argenx.com/news/2017/argenx-reports-first-quarter-2017-financial-results-and-provides-business-update2024-05-07T18:54:48.719Z1.0https://www.us.argenx.com/news/2017/argenx-reaches-50-enrollment-phase-2-clinical-trial-argx-113-myasthenia-gravis2024-05-07T18:54:48.237Z1.0https://www.us.argenx.com/news/2017/argenx-announces-launch-proposed-initial-public-offering-united-states2024-05-07T18:54:43.102Z1.0https://www.us.argenx.com/news/2017/argenx-announces-launch-proposed-initial-public-offering-united-states-02024-05-07T18:54:43.394Z1.0https://www.us.argenx.com/news/2017/argenx-announces-size-initial-public-offering-united-states-increased-5-million-adss2024-05-07T18:54:44.595Z1.0https://www.us.argenx.com/news/2017/argenx-raises-approximately-100-million-gross-proceeds-nasdaq-ipo2024-05-07T18:54:47.804Z1.0https://www.us.argenx.com/news/2017/argenx-announces-full-exercise-underwriters-option-purchase-additional-adss2024-05-07T18:54:42.774Z1.0https://www.us.argenx.com/news/2017/argenx-announces-closing-nasdaq-ipo2024-05-07T18:54:42.041Z1.0https://www.us.argenx.com/news/2017/argenx-present-jmp-securities-life-sciences-conference2024-05-07T18:54:46.634Z1.0https://www.us.argenx.com/news/2017/argenx-presents-update-phase-i-data-argx-110-expansion-study-patients-cutaneous-t-cell2024-05-07T18:54:47.491Z1.0https://www.us.argenx.com/news/2017/argenx-receives-second-preclinical-milestone-payment-collaboration-leo-pharma2024-05-07T18:54:48.541Z1.0https://www.us.argenx.com/news/2017/argenx-presents-full-data-argx-111-phase-ib-study-patients-advanced-cancers-over-expressing2024-05-07T18:54:47.328Z1.0https://www.us.argenx.com/news/2017/argenx-present-wedbush-pacgrow-healthcare-conference-02024-05-07T18:54:47.081Z1.0https://www.us.argenx.com/news/2017/argenx-host-conference-call-webcast-report-second-quarter-business-update-and-half-year-20172024-05-07T18:54:45.372Z1.0https://www.us.argenx.com/news/2017/argenx-announces-publication-nature-medicine-preclinical-data-supporting-therapeutic-potential2024-05-07T18:54:44.01Z1.0https://www.us.argenx.com/news/2017/argenx-reports-second-quarter-business-update-and-half-year-2017-financial-results2024-05-07T18:54:49.169Z1.0https://www.us.argenx.com/news/2017/argenx-reaches-50-enrollment-phase-2-clinical-trial-argx-113-immune-thrombocytopenia2024-05-07T18:54:48.097Z1.0https://www.us.argenx.com/news/2017/argenx-announces-orphan-drug-designation-argx-113-treatment-myasthenia-gravis2024-05-07T18:54:43.848Z1.0https://www.us.argenx.com/news/2017/argenx-launches-phase-ii-proof-concept-clinical-trial-argx-113-treatment-pemphigus-vulgaris2024-05-07T18:54:45.882Z1.0https://www.us.argenx.com/news/2017/invitation-extraordinary-shareholders-meeting2024-05-07T18:54:49.468Z1.0https://www.us.argenx.com/news/2017/argenx-reports-third-quarter-2017-financial-results-and2024-05-07T18:54:49.322Z1.0https://www.us.argenx.com/news/2017/argenx-launches-phase-i-trial-subcutaneous-formulation-argx-1132024-05-07T18:54:45.728Z1.0https://www.us.argenx.com/news/2017/argenx-host-kol-breakfast-symposium-pemphigus-vulgaris-november-10-20172024-05-07T18:54:45.523Z1.0https://www.us.argenx.com/news/2017/argenx-announces-results-extraordinary-shareholders-meeting-20172024-05-07T18:54:44.413Z1.0https://www.us.argenx.com/news/2017/argenx-present-upcoming-investor-conferences-02024-05-07T18:54:46.939Z1.0https://www.us.argenx.com/news/2017/argenx-provide-updates-phase-12-clinical-trials-argx-110-acute-myeloid-leukemia-and-cutaneous2024-05-07T18:54:47.657Z1.0https://www.us.argenx.com/news/2017/argenx-reports-positive-topline-results-phase-2-proof-concept-trial-argx-113-efgartigimod2024-05-07T18:54:49.023Z1.0https://www.us.argenx.com/news/2017/argenx-announces-launch-proposed-public-offering-united-states2024-05-07T18:54:43.678Z1.0https://www.us.argenx.com/news/2017/argenx-announces-size-proposed-public-offering-united-states-updated-35-million-adss2024-05-07T18:54:44.773Z1.0https://www.us.argenx.com/news/2017/argenx-raises-approximately-231-million-gross-proceeds-upsized-us-public-offering2024-05-07T18:54:47.95Z1.0https://www.us.argenx.com/news/2017/argenx-announces-closing-us-public-offering-gross-proceeds-approximately-266-million2024-05-07T18:54:42.188Z1.0https://www.us.argenx.com/news/20182024-05-07T18:54:49.59Z1.0https://www.us.argenx.com/news/2018/argenx-host-conference-call-webcast-report-fourth-quarter-business-update-and-full-year-20172024-05-07T18:54:49.703Z1.0https://www.us.argenx.com/news/2018/argenx-reports-fourth-quarter-business-update-and-full-year-2017-financial-results2024-05-07T18:55:18.588Z1.0https://www.us.argenx.com/news/2018/argenx-present-cowen-company-38th-annual-health-care-conference2024-05-07T18:55:16.929Z1.0https://www.us.argenx.com/news/2018/argenx-awarded-eu25-million-vlaio-grant-identify-novel-therapeutic-antibodies2024-05-07T18:55:15.516Z1.0https://www.us.argenx.com/news/2018/argenx-announces-expansion-its-pipeline-addition-complement-targeted-argx-117-treatment-severe2024-05-07T18:55:13.921Z1.0https://www.us.argenx.com/news/2018/argenx-announces-annual-general-meeting-shareholders-may-8-20182024-05-07T18:55:12.5Z1.0https://www.us.argenx.com/news/2018/argenx-announces-orphan-drug-designation-argx-113-treatment-myasthenia-gravis-europe2024-05-07T18:55:14.728Z1.0https://www.us.argenx.com/news/2018/argenx-present-complete-data-phase-2-clinical-trial-efgartigimod-argx-113-myasthenia-gravis2024-05-07T18:55:16.634Z1.0https://www.us.argenx.com/news/2018/argenx-appoints-keith-woods-chief-operating-officer2024-05-07T18:55:15.365Z1.0https://www.us.argenx.com/news/2018/argenx-receive-third-preclinical-milestone-payment-collaboration-leo-pharma2024-05-07T18:55:17.691Z1.0https://www.us.argenx.com/news/2018/argenx-present-complete-data-phase-2-proof-concept-trial-efgartigimod-argx-113-generalized2024-05-07T18:55:16.789Z1.0https://www.us.argenx.com/news/2018/argenx-announces-results-annual-general-meeting-shareholders2024-05-07T18:55:15.098Z1.0https://www.us.argenx.com/news/2018/argenx-reports-first-quarter-2018-financial-results-and-provides-business-update2024-05-07T18:55:18.443Z1.0https://www.us.argenx.com/news/2018/argenx-present-upcoming-investor-conferences-12024-05-07T18:55:17.098Z1.0https://www.us.argenx.com/news/2018/argenx-receives-feedback-fda-end-phase-2-meeting-efgartigimod-myasthenia-gravis2024-05-07T18:55:17.835Z1.0https://www.us.argenx.com/news/2018/argenx-selected-bel-20-index2024-05-07T18:55:19.47Z1.0https://www.us.argenx.com/news/2018/argenx-host-kol-breakfast-symposium-immune-thrombocytopenia2024-05-07T18:55:16.265Z1.0https://www.us.argenx.com/news/2018/argenx-announces-data-phase-1-study-efgartigimod-argx-113-subcutaneous-formulation2024-05-07T18:55:13.478Z1.0https://www.us.argenx.com/news/2018/argenx-reports-interim-data-first-cohort-phase-2-proof-concept-clinical-trial-efgartigimod2024-05-07T18:55:18.727Z1.0https://www.us.argenx.com/news/2018/argenx-receives-second-preclinical-milestone-payment-under-its-development-agreement-abbvie2024-05-07T18:55:18.29Z1.0https://www.us.argenx.com/news/2018/argenx-receives-milestone-payment-strategic-collaboration-shire2024-05-07T18:55:18.138Z1.0https://www.us.argenx.com/news/2018/argenx-announces-publication-full-data-phase-1-healthy-volunteer-study-efgartigimod-journal2024-05-07T18:55:14.923Z1.0https://www.us.argenx.com/news/2018/argenx-host-conference-call-webcast-report-second-quarter-business-update2024-05-07T18:55:16.121Z1.0https://www.us.argenx.com/news/2018/argenx-reports-second-quarter-business-update-and-half-year-2018-financial-results2024-05-07T18:55:19.056Z1.0https://www.us.argenx.com/news/2018/argenx-present-2018-wedbush-pacgrow-healthcare-conference2024-05-07T18:55:16.457Z1.0https://www.us.argenx.com/news/2018/argenx-announces-abbvie-has-exercised-its-exclusive-option-license-argx-115-novel-immuno2024-05-07T18:55:12.162Z1.0https://www.us.argenx.com/news/2018/argenx-receives-feedback-japans-pmda-phase-3-clinical-trial-and-regulatory-pathway2024-05-07T18:55:17.977Z1.0https://www.us.argenx.com/news/2018/argenx-doses-first-patient-global-phase-3-registration-trial-efgartigimod2024-05-07T18:55:15.814Z1.0https://www.us.argenx.com/news/2018/argenx-reports-positive-topline-results-phase-2-proof-concept-trial-efgartigimod-primary2024-05-07T18:55:18.891Z1.0https://www.us.argenx.com/news/2018/argenx-announces-launch-proposed-public-offering-united-states-02024-05-07T18:55:14.172Z1.0https://www.us.argenx.com/news/2018/argenx-raises-approximately-3006-million-gross-proceeds-us-public-offering2024-05-07T18:55:17.543Z1.0https://www.us.argenx.com/news/2018/argenx-announces-closing-us-public-offering2024-05-07T18:55:12.986Z1.0https://www.us.argenx.com/news/2018/argenx-awarded-eu26-million-vlaio-grant-explore-new-applications-abdeg-technology2024-05-07T18:55:15.669Z1.0https://www.us.argenx.com/news/2018/argenx-reports-third-quarter-2018-financial-results-and-provides-business-update2024-05-07T18:55:19.313Z1.0https://www.us.argenx.com/news/2018/argenx-announces-new-cusatuzumab-argx-110-aml-data-abstracts-published-connection-60th2024-05-07T18:55:14.481Z1.0https://www.us.argenx.com/news/2018/argenx-present-upcoming-investor-conferences-22024-05-07T18:55:17.247Z1.0https://www.us.argenx.com/news/2018/argenx-provides-detailed-data-phase-2-clinical-trial-efgartigimod-immune-thrombocytopenia-and2024-05-07T18:55:17.403Z1.0https://www.us.argenx.com/news/2018/argenx-enters-exclusive-global-collaboration-and-license-agreement-cilag-gmbh-international2024-05-07T18:55:15.962Z1.0https://www.us.argenx.com/news/20192024-05-07T18:55:19.6Z1.0https://www.us.argenx.com/news/2019/argenx-present-37th-annual-jp-morgan-healthcare-conference2024-05-07T18:55:22.245Z1.0https://www.us.argenx.com/news/2019/argenx-announces-closing-exclusive-global-collaboration-and-license-agreement-cusatuzumab-argx2024-05-07T18:55:20.004Z1.0https://www.us.argenx.com/news/2019/argenx-and-halozyme-enter-global-collaboration-and-license-agreement-enhanzer-technology2024-05-07T18:55:19.714Z1.0https://www.us.argenx.com/news/2019/argenx-host-conference-call-webcast-report-fourth-quarter-business-update-and-full-year-20182024-05-07T18:55:21.702Z1.0https://www.us.argenx.com/news/2019/argenx-reports-fourth-quarter-business-update-and-full-year-2018-financial-results2024-05-07T18:55:23.814Z1.0https://www.us.argenx.com/news/2019/argenx-present-cowen-and-company-39th-annual-health-care-conference2024-05-07T18:55:22.588Z1.0https://www.us.argenx.com/news/2019/argenx-receive-first-clinical-milestone-payment-product-candidate-developed2024-05-07T18:55:23.343Z1.0https://www.us.argenx.com/news/2019/argenx-announces-annual-general-meeting-shareholders-may-7-20192024-05-07T18:55:19.858Z1.0https://www.us.argenx.com/news/2019/argenx-announces-results-annual-general-meeting-shareholders-02024-05-07T18:55:21.272Z1.0https://www.us.argenx.com/news/2019/argenx-present-bank-america-merrill-lynch-2019-health-care-conference2024-05-07T18:55:22.434Z1.0https://www.us.argenx.com/news/2019/argenx-reports-first-quarter-2019-financial-results-and-provides-business-update2024-05-07T18:55:23.637Z1.0https://www.us.argenx.com/news/2019/argenx-host-rd-day-may-22-20192024-05-07T18:55:21.839Z1.0https://www.us.argenx.com/news/2019/argenx-announces-pipeline-expansion-and-argenx-2021-vision-build-integrated-immunology-company2024-05-07T18:55:20.632Z1.0https://www.us.argenx.com/news/2019/argenx-announces-publication-efgartigimod-phase-2-myasthenia-gravis-trial-results-neurology2024-05-07T18:55:20.771Z1.0https://www.us.argenx.com/news/2019/argenx-present-upcoming-investor-conferences-32024-05-07T18:55:23.026Z1.0https://www.us.argenx.com/news/2019/argenx-report-half-year-2019-financial-results-and-second-quarter-business-update-august-12024-05-07T18:55:23.497Z1.0https://www.us.argenx.com/news/2019/argenx-reports-half-year-2019-financial-results-and-second-quarter-business-update2024-05-07T18:55:23.984Z1.0https://www.us.argenx.com/news/2019/argenx-present-2019-wedbush-pacgrow-healthcare-conference2024-05-07T18:55:22.107Z1.0https://www.us.argenx.com/news/2019/argenx-present-morgan-stanley-17th-annual-global-healthcare-conference2024-05-07T18:55:22.876Z1.0https://www.us.argenx.com/news/2019/invitation-extraordinary-shareholders-meeting-02024-05-07T18:55:24.288Z1.0https://www.us.argenx.com/news/2019/argenx-reports-third-quarter-2019-financial-results-and-provides-business-update2024-05-07T18:55:24.147Z1.0https://www.us.argenx.com/news/2019/argenx-participate-upcoming-investor-conferences2024-05-07T18:55:21.971Z1.0https://www.us.argenx.com/news/2019/argenx-present-data-upcoming-61st-american-society-hematology-ash-annual-meeting2024-05-07T18:55:22.73Z1.0https://www.us.argenx.com/news/2019/argenx-announces-launch-proposed-global-offering2024-05-07T18:55:20.497Z1.0https://www.us.argenx.com/news/2019/argenx-raises-484-million-gross-proceeds-global-offering2024-05-07T18:55:23.205Z1.0https://www.us.argenx.com/news/2019/argenx-announces-full-exercise-underwriters-option-purchase-additional-adss-02024-05-07T18:55:20.351Z1.0https://www.us.argenx.com/news/2019/argenx-announces-closing-global-offering2024-05-07T18:55:20.206Z1.0https://www.us.argenx.com/news/2019/argenx-announces-results-extraordinary-general-meeting-shareholders2024-05-07T18:55:21.417Z1.0https://www.us.argenx.com/news/2019/argenx-announces-upcoming-investor-events2024-05-07T18:55:21.558Z1.0https://www.us.argenx.com/news/2019/argenx-announces-receipt-first-milestone-payment-under-janssen-collaboration-and-provides-data2024-05-07T18:55:21.051Z1.0https://www.us.argenx.com/news/2019/argenx-announces-publication-efgartigimod-phase-2-primary-immune-thrombocytopenia-trial2024-05-07T18:55:20.914Z1.0https://www.us.argenx.com/news/20202024-05-07T18:55:24.395Z1.0https://www.us.argenx.com/news/2020/argenx-provides-strategic-outlook-advancing-late-stage-pipeline-towards-argenx-2021-vision2024-05-07T18:55:27.656Z1.0https://www.us.argenx.com/news/2020/argenx-report-full-year-2019-financial-results-and-fourth-quarter-business-update-february-272024-05-07T18:55:28.087Z1.0https://www.us.argenx.com/news/2020/argenx-present-cowen-40th-annual-health-care-conference2024-05-07T18:55:27.024Z1.0https://www.us.argenx.com/news/2020/argenx-full-year-2019-financial-results2024-05-07T18:55:25.938Z1.0https://www.us.argenx.com/news/2020/argenx-announces-annual-general-meeting-shareholders-may-12-20202024-05-07T18:55:24.511Z1.0https://www.us.argenx.com/news/2020/argenx-present-bofa-securities-virtual-health-care-conference-20202024-05-07T18:55:26.878Z1.0https://www.us.argenx.com/news/2020/argenx-report-first-quarter-2020-financial-results-and-business-update-may-14-20202024-05-07T18:55:27.943Z1.0https://www.us.argenx.com/news/2020/argenx-present-data-phase-2-trial-efgartigimod-pemphigus-2020-society-investigative2024-05-07T18:55:27.201Z1.0https://www.us.argenx.com/news/2020/argenx-announces-results-annual-general-meeting-shareholders-12024-05-07T18:55:25.472Z1.0https://www.us.argenx.com/news/2020/argenx-reports-first-quarter-2020-financial-results-and-provides-business-update2024-05-07T18:55:28.53Z1.0https://www.us.argenx.com/news/2020/argenx-announces-positive-topline-phase-3-adapt-trial-results2024-05-07T18:55:25.319Z1.0https://www.us.argenx.com/news/2020/argenx-announces-launch-proposed-global-offering-02024-05-07T18:55:25.124Z1.0https://www.us.argenx.com/news/2020/argenx-raises-750-million-gross-proceeds-global-offering2024-05-07T18:55:27.799Z1.0https://www.us.argenx.com/news/2020/argenx-announces-full-exercise-underwriters-option-purchase-additional-adss-12024-05-07T18:55:24.957Z1.0https://www.us.argenx.com/news/2020/argenx-announces-closing-global-offering-02024-05-07T18:55:24.65Z1.0https://www.us.argenx.com/news/2020/argenx-present-goldman-sachs-41st-annual-global-healthcare-conference2024-05-07T18:55:27.363Z1.0https://www.us.argenx.com/news/2020/argenx-announces-closing-global-offering-12024-05-07T18:55:24.805Z1.0https://www.us.argenx.com/news/2020/argenx-report-half-year-2020-financial-results-and-second-quarter-business-update-july-30-20202024-05-07T18:55:28.226Z1.0https://www.us.argenx.com/news/2020/argenx-reports-half-year-2020-financial-results-and-provides-second-quarter-business-update2024-05-07T18:55:28.706Z1.0https://www.us.argenx.com/news/2020/argenx-present-2020-wedbush-pacgrow-healthcare-virtual-conference2024-05-07T18:55:26.582Z1.0https://www.us.argenx.com/news/2020/argenx-management-present-upcoming-virtual-investor-conferences2024-05-07T18:55:26.107Z1.0https://www.us.argenx.com/news/2020/argenx-present-additional-data-global-phase-3-adapt-trial-efgartigimod-myasthenia-gravis2024-05-07T18:55:26.728Z1.0https://www.us.argenx.com/news/2020/argenx-presents-additional-efgartigimod-data-global-phase-3-adapt-trial-myasthenia-gravis2024-05-07T18:55:27.513Z1.0https://www.us.argenx.com/news/2020/argenx-expands-capabilities-antibody-engineering-through-key-technology-partnerships2024-05-07T18:55:25.765Z1.0https://www.us.argenx.com/news/2020/argenx-report-third-quarter-2020-financial-results-and-business-update-october-22-20202024-05-07T18:55:28.368Z1.0https://www.us.argenx.com/news/2020/argenx-reports-third-quarter-2020-financial-results-and-provides-business-update2024-05-07T18:55:28.861Z1.0https://www.us.argenx.com/news/2020/argenx-participate-upcoming-virtual-investor-conferences2024-05-07T18:55:26.252Z1.0https://www.us.argenx.com/news/2020/argenx-premieres-mystery-me-docuseries-inspired-myasthenia-gravis-patient-experience2024-05-07T18:55:26.411Z1.0https://www.us.argenx.com/news/2020/argenx-enters-agreement-acquire-priority-review-voucher2024-05-07T18:55:25.624Z1.0https://www.us.argenx.com/news/20212024-05-07T18:55:28.997Z1.0https://www.us.argenx.com/news/2021/argenx-present-39th-annual-jp-morgan-healthcare-conference2024-05-07T18:55:32.124Z1.0https://www.us.argenx.com/news/2021/argenx-and-zai-lab-announce-strategic-collaboration-efgartigimod-greater-china2024-05-07T18:55:29.114Z1.0https://www.us.argenx.com/news/2021/argenx-announces-2021-corporate-priorities-and-highlights-recent-achievements-across2024-05-07T18:55:29.27Z1.0https://www.us.argenx.com/news/2021/argenx-announces-go-decision-adhere-trial-efgartigimod-chronic-inflammatory-demyelinating2024-05-07T18:55:30.013Z1.0https://www.us.argenx.com/news/2021/argenx-announces-launch-proposed-global-offering-12024-05-07T18:55:30.23Z1.0https://www.us.argenx.com/news/2021/argenx-issues-statement-concerning-efgartigimod2024-05-07T18:55:31.633Z1.0https://www.us.argenx.com/news/2021/argenx-raises-10-billion-gross-proceeds-global-offering2024-05-07T18:55:32.915Z1.0https://www.us.argenx.com/news/2021/argenx-announces-full-exercise-underwriters-option-purchase-additional-adss-22024-05-07T18:55:29.87Z1.0https://www.us.argenx.com/news/2021/argenx-announces-closing-global-offering-22024-05-07T18:55:29.576Z1.0https://www.us.argenx.com/news/2021/argenx-report-full-year-2020-financial-results-and-fourth-quarter-business-update-march-4-20212024-05-07T18:55:33.408Z1.0https://www.us.argenx.com/news/2021/argenx-announces-fda-acceptance-bla-filing-efgartigimod-treatment-generalized-myasthenia2024-05-07T18:55:29.724Z1.0https://www.us.argenx.com/news/2021/argenx-reports-full-year-2020-financial-results-and-provides-fourth-quarter-business-update2024-05-07T18:55:34.094Z1.0https://www.us.argenx.com/news/2021/argenx-announces-annual-general-meeting-shareholders-may-11-20212024-05-07T18:55:29.425Z1.0https://www.us.argenx.com/news/2021/argenx-management-present-upcoming-virtual-investor-conferences-02024-05-07T18:55:31.786Z1.0https://www.us.argenx.com/news/2021/argenx-report-first-quarter-2021-financial-results-and-business-update-may-14-20212024-05-07T18:55:33.247Z1.0https://www.us.argenx.com/news/2021/argenx-announces-results-annual-general-meeting-shareholders-22024-05-07T18:55:30.571Z1.0https://www.us.argenx.com/news/2021/argenx-reports-first-quarter-2021-financial-results-and-provides-business-update2024-05-07T18:55:33.9Z1.0https://www.us.argenx.com/news/2021/argenx-present-upcoming-investor-conferences-42024-05-07T18:55:32.367Z1.0https://www.us.argenx.com/news/2021/argenx-appoints-karl-gubitz-chief-financial-officer2024-05-07T18:55:31.1Z1.0https://www.us.argenx.com/news/2021/argenx-regain-global-rights-cusatuzumab2024-05-07T18:55:33.073Z1.0https://www.us.argenx.com/news/2021/argenx-announces-publication-phase-3-adapt-trial-results-efgartigimod-treatment-generalized2024-05-07T18:55:30.408Z1.0https://www.us.argenx.com/news/2021/argenx-host-virtual-rd-day-july-20-20212024-05-07T18:55:31.491Z1.0https://www.us.argenx.com/news/2021/argenx-report-half-year-2021-financial-results-and-second-quarter-business-update-july-29-20212024-05-07T18:55:33.56Z1.0https://www.us.argenx.com/news/2021/argenx-reports-half-year-2021-financial-results-and-provides-second-quarter-business-update2024-05-07T18:55:34.345Z1.0https://www.us.argenx.com/news/2021/argenx-present-2021-wedbush-pacgrow-virtual-healthcare-conference2024-05-07T18:55:31.957Z1.0https://www.us.argenx.com/news/2021/argenx-announces-validation-european-marketing-authorization-application-efgartigimod2024-05-07T18:55:30.904Z1.0https://www.us.argenx.com/news/2021/argenx-present-upcoming-investor-conferences-52024-05-07T18:55:32.561Z1.0https://www.us.argenx.com/news/2021/argenx-highlight-potential-first-class-fcrn-antagonist-efgartigimod-upcoming-neuromuscular2024-05-07T18:55:31.334Z1.0https://www.us.argenx.com/news/2021/argenx-report-third-quarter-2021-financial-results-and-business-update-october-28-20212024-05-07T18:55:33.72Z1.0https://www.us.argenx.com/news/2021/argenx-reports-third-quarter-2021-financial-results-and-provides-business-update2024-05-07T18:55:34.517Z1.0https://www.us.argenx.com/news/2021/argenx-present-upcoming-investor-conferences-62024-05-07T18:55:32.736Z1.0https://www.us.argenx.com/news/2021/argenx-announces-us-food-and-drug-administration-fda-approval-vyvgarttm-efgartigimod-alfa-fcab2024-05-07T18:55:30.727Z1.0https://www.us.argenx.com/news/20222024-05-07T18:55:34.64Z1.0https://www.us.argenx.com/news/2022/argenx-present-40th-annual-jp-morgan-healthcare-conference2024-05-07T18:55:37.147Z1.0https://www.us.argenx.com/news/2022/argenx-highlights-strategic-priorities-20222024-05-07T18:55:36.765Z1.0https://www.us.argenx.com/news/2022/argenx-announces-vyvgarttm-approval-japan-treatment-generalized-myasthenia-gravis2024-05-07T18:55:36.588Z1.0https://www.us.argenx.com/news/2022/argenx-present-11th-annual-svb-leerink-global-healthcare-conference2024-05-07T18:55:36.936Z1.0https://www.us.argenx.com/news/2022/argenx-report-full-year-2021-financial-results-and-fourth-quarter-business-update-march-3-20222024-05-07T18:55:38.797Z1.0https://www.us.argenx.com/news/2022/argenx-present-42nd-annual-cowen-health-care-conference2024-05-07T18:55:37.329Z1.0https://www.us.argenx.com/news/2022/argenx-reports-full-year-2021-financial-results-and-provides-fourth-quarter-business-update2024-06-11T05:43:03.379Z1.0https://www.us.argenx.com/news/2022/argenx-announces-positive-topline-phase-3-data-adapt-sc-study-evaluating-subcutaneous2024-05-07T18:55:35.798Z1.0https://www.us.argenx.com/news/2022/argenx-announces-launch-proposed-global-offering-22024-05-07T18:55:35.433Z1.0https://www.us.argenx.com/news/2022/argenx-raises-700-million-gross-proceeds-global-offering2024-05-07T18:55:38.268Z1.0https://www.us.argenx.com/news/2022/argenx-announces-closing-global-offering-32024-05-07T18:55:34.952Z1.0https://www.us.argenx.com/news/2022/argenx-announces-annual-general-meeting-shareholders-may-10-20222024-05-07T18:55:34.762Z1.0https://www.us.argenx.com/news/2022/argenx-announces-full-exercise-underwriters-option-purchase-additional-adss-32024-05-07T18:55:35.172Z1.0https://www.us.argenx.com/news/2022/argenx-present-new-data-generalized-myasthenia-gravis-program-2022-american-academy-neurology2024-05-07T18:55:37.684Z1.0https://www.us.argenx.com/news/2022/argenx-presents-interim-results-adapt-open-label-extension-study-evaluating-vyvgartr2024-05-07T18:55:38.082Z1.0https://www.us.argenx.com/news/2022/argenx-report-first-quarter-2022-financial-results-and-business-update-may-5-20222024-05-07T18:55:38.634Z1.0https://www.us.argenx.com/news/2022/argenx-present-bofa-securities-2022-healthcare-conference2024-05-07T18:55:37.509Z1.0https://www.us.argenx.com/news/2022/argenx-reports-first-quarter-2022-financial-results-and-provides-business-update2024-07-03T09:21:19.472Z1.0https://www.us.argenx.com/news/2022/argenx-announces-positive-phase-3-data-advance-trial-vyvgartr-efgartigimod-alfa-fcab-adults2024-05-07T18:55:35.626Z1.0https://www.us.argenx.com/news/2022/argenx-announces-results-annual-general-meeting-shareholders-32024-05-07T18:55:36.198Z1.0https://www.us.argenx.com/news/2022/argenx-announces-publication-translational-data-efgartigimod-autoimmune-skin-blistering2024-05-07T18:55:35.996Z1.0https://www.us.argenx.com/news/2022/argenx-announces-uk-mhra-has-granted-early-access-efgartigimod-generalized-myasthenia-gravis2024-05-07T18:55:36.411Z1.0https://www.us.argenx.com/news/2022/argenx-present-upcoming-investor-conferences-72024-05-07T18:55:37.855Z1.0https://www.us.argenx.com/news/2022/argenx-receives-positive-chmp-opinion-efgartigimod-treatment-adult-patients-generalized2024-05-07T18:55:38.445Z1.0https://www.us.argenx.com/news/2022/argenx-report-half-year-2022-financial-results-and-second-quarter-business-update-july-28-20222024-05-07T18:56:00.666Z1.0https://www.us.argenx.com/news/2022/argenx-reports-half-year-2022-financial-results-and-provides-second-quarter-business-update2024-07-03T09:31:46.804Z1.0https://www.us.argenx.com/news/2022/argenx-announces-european-commission-approval-vyvgarttm-efgartigimod-alfa-fcab-treatment2024-05-07T18:55:57.946Z1.0https://www.us.argenx.com/news/2022/argenx-present-wells-fargo-healthcare-conference2024-05-07T18:56:00.51Z1.0https://www.us.argenx.com/news/2022/argenx-appoints-camilla-sylvest-board-directors2024-05-07T18:55:59.293Z1.0https://www.us.argenx.com/news/2022/argenx-highlight-key-programs-neuromuscular-franchise-upcoming-medical-meetings2024-05-07T18:55:59.914Z1.0https://www.us.argenx.com/news/2022/argenx-submits-biologics-license-application-us-food-and-drug-administration-subcutaneous2024-05-07T18:56:01.536Z1.0https://www.us.argenx.com/news/2022/argenx-report-third-quarter-2022-financial-results-and-business-update-october-27-20222024-05-07T18:56:00.827Z1.0https://www.us.argenx.com/news/2022/argenx-reports-third-quarter-2022-financial-results-and-provides-business-update2024-07-03T09:09:59.548Z1.0https://www.us.argenx.com/news/2022/argenx-announces-extraordinary-general-meeting-shareholders-december-12-20222024-05-07T18:55:58.501Z1.0https://www.us.argenx.com/news/2022/argenx-present-upcoming-investor-conferences-82024-05-07T18:56:00.333Z1.0https://www.us.argenx.com/news/2022/argenx-announces-us-fda-acceptance-biologics-license-application-subcutaneous-efgartigimod2024-05-07T18:55:58.895Z1.0https://www.us.argenx.com/news/2022/argenx-enters-agreement-acquire-priority-review-voucher-20222024-05-07T18:55:59.523Z1.0https://www.us.argenx.com/news/2022/argenx-present-pivotal-advance-trial-data-during-ash-plenary-session-highlighting-vyvgartr2024-05-07T18:56:00.181Z1.0https://www.us.argenx.com/news/2022/argenx-appoints-ana-cespedes-board-directors2024-05-07T18:55:59.133Z1.0https://www.us.argenx.com/news/20232024-05-07T18:56:01.699Z1.0https://www.us.argenx.com/news/2023/argenx-present-41st-annual-jp-morgan-healthcare-conference2024-05-07T18:56:05.19Z1.0https://www.us.argenx.com/news/2023/argenx-highlights-2023-strategic-priorities-across-immunology-pipeline2024-05-07T18:56:04.651Z1.0https://www.us.argenx.com/news/2023/argenx-announces-extraordinary-general-meeting-shareholders-february-27-2023-appoint-steve2024-05-07T18:56:02.74Z1.0https://www.us.argenx.com/news/2023/argenx-receives-notification-pdufa-date-extension-sc-efgartigimod2024-05-07T18:56:06.3Z1.0https://www.us.argenx.com/news/2023/argenx-report-full-year-2022-financial-results-and-fourth-quarter-business-update-march-2-20232024-05-07T18:56:06.607Z1.0https://www.us.argenx.com/news/2023/argenx-appoints-steve-krognes-board-directors2024-05-07T18:56:04.28Z1.0https://www.us.argenx.com/news/2023/argenx-reports-full-year-2022-financial-results-and-provides-fourth-quarter-business-update2024-07-03T09:42:46.95Z1.0https://www.us.argenx.com/news/2023/argenx-announces-planned-transition-chief-operating-officer2024-05-07T18:56:03.21Z1.0https://www.us.argenx.com/news/2023/argenx-present-upcoming-investor-conferences-92024-05-07T18:56:05.994Z1.0https://www.us.argenx.com/news/2023/argenx-announces-uk-mhra-approval-vyvgart-treatment-generalized-myasthenia-gravis2024-05-07T18:56:03.711Z1.0https://www.us.argenx.com/news/2023/argenx-announces-annual-general-meeting-shareholders-may-2-20232024-05-07T18:56:02.25Z1.0https://www.us.argenx.com/news/2023/argenx-and-genmab-enter-partnership-advance-antibody-therapies-immunology-and-oncology2024-05-07T18:56:01.818Z1.0https://www.us.argenx.com/news/2023/argenx-demonstrates-commitment-redefining-treatment-goals-generalized-myasthenia-gravis2024-05-07T18:56:04.466Z1.0https://www.us.argenx.com/news/2023/argenx-report-first-quarter-2023-financial-results-and-business-update-may-4-20232024-05-07T18:56:06.459Z1.0https://www.us.argenx.com/news/2023/argenx-present-bofa-securities-2023-health-care-conference2024-05-07T18:56:05.36Z1.0https://www.us.argenx.com/news/2023/argenx-announces-results-annual-general-meeting-shareholders-may-20232024-05-07T18:56:03.527Z1.0https://www.us.argenx.com/news/2023/argenx-reports-first-quarter-2023-financial-results-and-provides-business-update2024-07-03T09:37:06.306Z1.0https://www.us.argenx.com/news/2023/argenx-present-upcoming-investor-conferences-102024-05-07T18:56:05.521Z1.0https://www.us.argenx.com/news/2023/argenx-initiates-second-cohort-phase-2-arda-study-empasiprubart-multifocal-motor-neuropathy2024-05-07T18:56:05.017Z1.0https://www.us.argenx.com/news/2023/argenx-announces-us-food-and-drug-administration-approval-vyvgart-hytrulo-efgartigimod-alfa2024-05-07T18:56:03.873Z1.0https://www.us.argenx.com/news/2023/argenx-and-zai-lab-announce-approval-vyvgartr-efgartigimod-alfa-injection-generalized2024-05-07T18:56:02.051Z1.0https://www.us.argenx.com/news/2023/argenx-reports-positive-topline-data-adhere-study-vyvgart-hytrulo-patients-chronic2024-05-07T18:56:07.754Z1.0https://www.us.argenx.com/news/2023/argenx-announces-launch-proposed-global-offering-32024-05-07T18:56:03.045Z1.0https://www.us.argenx.com/news/2023/argenx-raises-11-billion-gross-proceeds-global-offering2024-05-07T18:56:06.143Z1.0https://www.us.argenx.com/news/2023/argenx-announces-full-exercise-underwriters-option-purchase-additional-adss-42024-05-07T18:56:02.898Z1.0https://www.us.argenx.com/news/2023/argenx-report-half-year-2023-financial-results-and-second-quarter-business-update-july-27-20232024-05-07T18:56:06.757Z1.0https://www.us.argenx.com/news/2023/argenx-announces-closing-global-offering-07-232024-05-07T18:56:02.415Z1.0https://www.us.argenx.com/news/2023/argenx-reports-half-year-2023-financial-results-and-provides-second-quarter-business-update2024-07-03T08:28:20.049Z1.0https://www.us.argenx.com/news/2023/argenx-present-upcoming-investor-conferences-112024-05-07T18:56:05.659Z1.0https://www.us.argenx.com/news/2023/argenx-announces-positive-chmp-opinion-subcutaneous-efgartigimod-generalized-myasthenia-gravis2024-05-07T18:56:03.376Z1.0https://www.us.argenx.com/news/2023/argenx-announces-vyvgart-efgartigimod-alfa-authorized-sale-health-canada-generalized2024-05-07T18:56:04.09Z1.0https://www.us.argenx.com/news/2023/argenx-report-third-quarter-2023-financial-results-and-business-update-october-31-20232024-09-18T09:29:38.448Z1.0https://www.us.argenx.com/news/2023/argenx-reports-third-quarter-2023-financial-results-and-provides-business-update2024-07-03T08:47:20.526Z1.0https://www.us.argenx.com/news/2023/argenx-highlights-data-evaluating-vyvgart-neuromuscular-autoimmune-disease-aanem-and-mgfa2024-09-18T09:24:46.176Z1.0https://www.us.argenx.com/news/2023/argenx-present-upcoming-investor-conferences-122024-05-07T18:56:05.832Z1.0https://www.us.argenx.com/news/2023/argenx-announces-european-commission-approval-subcutaneous-vyvgartr-efgartigimod-alfa2024-05-07T18:56:02.579Z1.0https://www.us.argenx.com/news/2023/argenx-reports-topline-results-advance-sc-study-vyvgart-hytrulo-primary-immune2024-05-07T18:56:08.256Z1.0https://www.us.argenx.com/news/2023/argenx-reports-topline-results-address-study-efgartigimod-sc-pemphigus2024-05-07T18:56:08.091Z1.0https://www.us.argenx.com/news/20242024-05-07T18:56:08.378Z1.0https://www.us.argenx.com/news/2024/argenx-present-42nd-annual-jp-morgan-healthcare-conference2024-05-27T10:57:09.065Z1.0https://www.us.argenx.com/news/2024/argenx-highlights-2024-strategic-priorities2024-05-27T10:57:36.776Z1.0https://www.us.argenx.com/news/2024/argenx-announces-approval-vyvdurar-efgartigimod-alfa-and-hyaluronidase-qvfc-injection2024-10-16T12:58:17.293Z1.0https://www.us.argenx.com/news/2024/argenx-announces-fda-acceptance-supplemental-biologics-license-application-priority-review2024-05-27T10:58:41.768Z1.0https://www.us.argenx.com/news/2024/argenx-report-full-year-2023-financial-results-and-fourth-quarter-business-update-february-292024-05-27T10:59:00.419Z1.0https://www.us.argenx.com/news/2024/argenx-present-upcoming-investor-conferences-march-20242024-05-27T10:59:16.55Z1.0https://www.us.argenx.com/news/2024/argenx-reports-full-year-2023-financial-results-and-provides-fourth-quarter-business-update2024-07-03T09:47:33.161Z1.0https://www.us.argenx.com/news/2024/argenx-delivers-promise-transform-patient-expectations-autoimmunity-american-academy-neurology2024-05-27T10:59:53.93Z1.0https://www.us.argenx.com/news/2024/argenx-announces-approval-vyvgart-efgartigimod-alfa-japan-adults-primary-immune2024-05-27T11:00:13.231Z1.0https://www.us.argenx.com/news/2024/argenx-announces-annual-general-meeting-shareholders-may-7-20242024-05-27T11:00:33.258Z1.0https://www.us.argenx.com/news/2024/argenx-advances-clinical-development-efgartigimod-primary-sjogrens-disease2024-06-06T13:24:51.834Z1.0https://www.us.argenx.com/news/2024/argenx-data-highlight-evidence-vyvgart-and-vyvgart-hytrulo-drive-transformative-outcomes2024-07-25T13:58:50.164Z1.0https://www.us.argenx.com/news/2024/argenx-report-first-quarter-2024-financial-results-and-business-update-may-9-20242024-07-25T14:00:54.682Z1.0https://www.us.argenx.com/news/2024/argenx-present-bofa-securities-2024-health-care-conference2024-07-25T14:02:13.559Z1.0https://www.us.argenx.com/news/2024/argenx-announces-results-annual-general-meeting-shareholders-42024-07-25T14:03:36.091Z1.0https://www.us.argenx.com/news/2024/argenx-reports-first-quarter-2024-financial-results-and-provides-business-update2024-07-25T14:04:51.569Z1.0https://www.us.argenx.com/news/2024/argenx-present-goldman-sachs-45th-annual-global-healthcare-conference2024-07-25T14:06:27.545Z1.0https://www.us.argenx.com/news/2024/argenx-unveil-its-vision-2030-taking-breakthrough-science-50000-patients-during-its-upcoming2024-07-25T14:07:40.241Z1.0https://www.us.argenx.com/news/2024/argenx-announces-fda-approval-vyvgart-hytrulo-chronic-inflammatory-demyelinating-polyneuropathy2024-07-25T14:11:17.322Z1.0https://www.us.argenx.com/news/2024/argenx-highlights-breadth-autoimmune-pipeline-new-multifocal-motor-neuropathy-data-20242024-07-25T14:12:21.037Z1.0https://www.us.argenx.com/news/2024/argenx-and-zai-lab-announce-approval-efgartigimod-alfa-injection-subcutaneous-injection2024-07-25T14:13:57.783Z1.0https://www.us.argenx.com/news/2024/argenx-report-half-year-2024-financial-results-and-second-quarter-business-update-july-25-20242024-07-25T14:15:36.033Z1.0https://www.us.argenx.com/news/2024/argenx-reports-half-year-2024-financial-results-and-provides-second-quarter-business-update2024-07-25T14:16:46.779Z1.0https://www.us.argenx.com/news/2024/argenx-present-upcoming-investor-conferences-september-20242024-09-16T10:27:30.507Z1.0https://www.us.argenx.com/news/2024/argenx-announces-publication-in-the-lancet-neurology-of-pivotal-2024-09-19T05:00:15.901Z1.0https://www.us.argenx.com/news/2024/argenx-highlights-data-showing-patient-impact-across-multiple-im2024-10-15T12:18:05.175Z1.0https://www.us.argenx.com/news/2024/argenx-to-report-third-quarter-2024-financial-results-and-business-update-on-october-31-20242024-11-12T08:57:05.776Z1.0https://www.us.argenx.com/news/2024/argenx-reports-third-quarter-2024-financial-results-and-provides-business-update2024-10-31T06:07:16.501Z1.0https://www.us.argenx.com/news/2024/argenx-to-participate-at-upcoming-investor-conferences2024-11-12T06:05:52.92Z1.0https://www.us.argenx.com/news/2024/argenx-and-zai-lab-announce-approval-of-vyvgart-hytrulo-for-chro2024-11-12T08:41:14.358Z1.0https://www.us.argenx.com/news/2024/argenx-advances-clinical-development-of-efgartigimod-sc-in-idiopathic-inflammatory-myopathies2024-11-20T10:11:41.735Z1.0https://www.us.argenx.com/news/2024/argenx-to-present-at-upcoming-investor-conferences2024-11-26T05:43:53.353Z1.0https://www.us.argenx.com/news/2024/argenx-announces-approval-of-vyvdura--efgartigimod-alfa-and-hyal2024-12-27T05:55:39.019Z1.0https://www.us.argenx.com/news/2024/argenx-to-present-at-43rd-annual-j-p--morgan-healthcare-conferen2025-01-06T06:01:33.852Z1.0https://www.us.argenx.com/news/2024/argenx-highlights-2025-strategic-priorities2025-01-13T12:54:07.775Z1.0https://www.us.argenx.com/news/2024/argenx-presents-new-efgartigimod-data-at-eular-2025-highlighting2025-06-11T07:21:41.039Z1.0https://www.us.argenx.com/news/all2024-08-09T13:54:08.537Z1.0https://www.us.argenx.com/news/20252025-09-11T12:32:33.327Z1.0https://www.us.argenx.com/news/2025/press-release-31404872025-09-11T12:32:34.758Z1.0https://www.us.argenx.com/news/2025/press-release-31381922025-09-11T12:32:35.967Z1.0https://www.us.argenx.com/news/2025/press-release-31353952025-09-11T12:32:37.841Z1.0https://www.us.argenx.com/news/2025/press-release-31315202025-09-11T12:32:39.935Z1.0https://www.us.argenx.com/news/2025/press-release-31246402025-09-11T12:32:41.833Z1.0https://www.us.argenx.com/news/2025/press-release-31207362025-09-11T12:32:44.237Z1.0https://www.us.argenx.com/news/2025/press-release-31071322025-09-11T12:32:46.494Z1.0https://www.us.argenx.com/news/2025/press-release-31028792025-09-11T12:32:48.893Z1.0https://www.us.argenx.com/news/2025/press-release-30972062025-09-11T12:32:50.832Z1.0https://www.us.argenx.com/news/2025/press-release-30924302025-09-11T12:32:53.904Z1.0https://www.us.argenx.com/news/2025/press-release-30899072025-09-11T12:32:56.348Z1.0https://www.us.argenx.com/news/2025/press-release-30768042025-09-11T12:32:58.971Z1.0https://www.us.argenx.com/news/2025/press-release-30746672025-09-11T12:33:01.651Z1.0https://www.us.argenx.com/news/2025/press-release-30720492025-09-11T12:33:04.276Z1.0https://www.us.argenx.com/news/2025/press-release-30688792025-09-11T12:33:06.341Z1.0https://www.us.argenx.com/news/2025/press-release-30603182025-09-11T12:33:08.757Z1.0https://www.us.argenx.com/news/2025/press-release-30597742025-09-11T12:33:11.208Z1.0https://www.us.argenx.com/news/2025/press-release-30573072025-09-11T12:33:13.461Z1.0https://www.us.argenx.com/news/2025/press-release-30387342025-09-11T12:33:16.368Z1.0https://www.us.argenx.com/news/2025/press-release-30334872025-09-11T12:33:18.89Z1.0https://www.us.argenx.com/news/2025/press-release-31611942025-10-03T20:04:12.05Z1.0https://www.us.argenx.com/news/2025/press-release-31667782025-10-15T05:01:02.246Z1.0https://www.us.argenx.com/news/2025/press-release-31716542025-10-23T05:01:01.676Z1.0https://www.us.argenx.com/news/2025/press-release-31766352025-10-29T15:03:49.009Z1.0https://www.us.argenx.com/news/2025/press-release-31770522025-10-30T06:02:00.721Z1.0https://www.us.argenx.com/news/2025/press-release-31904712025-11-18T21:03:48.451Z1.0https://www.us.argenx.com/news/2025/press-release-32050932025-12-15T06:02:00.906Z1.0https://www.us.argenx.com/news/20262026-01-05T16:48:13.447Z1.0https://www.us.argenx.com/news/2026/press-release-32124182026-01-05T16:48:14.206Z1.0https://www.us.argenx.com/news/2026/press-release-32133092026-01-06T06:01:00.553Z1.0https://www.us.argenx.com/news/2026/press-release-32165312026-01-12T06:02:01.288Z1.0https://www.us.argenx.com/news/2026/press-release-32174572026-01-13T06:02:01.863Z1.0https://www.us.argenx.com/news/2026/press-release-32407692026-02-19T06:02:01.708Z1.0https://www.us.argenx.com/news/2026/press-release-32423022026-02-23T06:01:01.311Z1.0https://www.us.argenx.com/news/2026/press-release-32451832026-02-26T19:32:13.016Z1.0https://www.us.argenx.com/news/2026/press-release-32451992026-02-26T06:02:01.059Z1.0https://www.us.argenx.com/news/2026/press-release-32508042026-03-06T06:01:01.86Z1.0https://www.us.argenx.com/news/2026/press-release-32599412026-03-20T20:03:10.875Z1.0https://www.us.argenx.com/errors2024-05-14T16:56:00.693Z1.0https://www.us.argenx.com/errors/4042024-09-04T12:24:08.425Z1.0https://www.us.argenx.com/errors/5002024-09-04T12:23:24.653Z1.0https://www.us.argenx.com/disclaimer2024-08-01T04:56:23.182Z1.0https://www.us.argenx.com/cookie-policy2024-09-04T07:44:58.055Z1.0https://www.us.argenx.com/grants2026-03-23T18:44:02.204Z1.0https://www.us.argenx.com/information-notices-argenx-affiliates2024-08-01T06:42:43.894Z1.0https://www.us.argenx.com/privacy-policy2025-09-25T12:35:43.304Z1.0https://www.us.argenx.com/privacy-policy/pharmacovigilance-privacy-notice2025-03-27T06:06:55.426Z1.0https://www.us.argenx.com/privacy-policy/healthcare-professionals-privacy-notice2025-03-25T05:52:59.629Z1.0https://www.us.argenx.com/privacy-policy/us-supplemental-privacy-notice2025-09-25T12:23:39.498Z1.0https://www.us.argenx.com/contact-us2025-08-25T13:57:03.226Z1.0https://www.us.argenx.com/pipeline2026-03-18T03:45:23.589Z1.0https://www.us.argenx.com/pipeline/efgartigimod2025-12-23T04:13:28.228Z1.0https://www.us.argenx.com/pipeline/argx-1182024-08-07T09:53:00.059Z1.0https://www.us.argenx.com/pipeline/empasiprubart2025-12-17T03:06:10.365Z1.0https://www.us.argenx.com/pipeline/2020-sid-annual-meeting-virtual-conference2024-08-01T11:42:24.637Z1.0https://www.us.argenx.com/instructions-for_use-prefilled-syringe2025-03-06T21:02:08.32Z1.0https://www.us.argenx.com/on-site-storage-and-temperature-monitoring2026-03-12T16:28:32.98Z1.0https://www.us.argenx.com/return-and-destruction-process2025-03-13T08:21:49.953Z1.0https://www.us.argenx.com/reporting-temperature-deviation2025-03-13T07:44:56.958Z1.0https://www.us.argenx.com/reporting-product-quality-complaint2025-03-13T08:19:47.88Z1.0https://www.us.argenx.com/grants-fcrn-inhibition-for-the-treatment-of-myasthenia-gravis2024-08-14T10:14:13.743Z1.0https://www.us.argenx.com/addressing-knowledge-gaps-in-generalized-myasthenia-gravis-care2024-08-14T11:34:57.586Z1.0https://www.us.argenx.com/patient-access-to-investigational-therapies2024-10-31T11:31:18.029Z1.0https://www.us.argenx.com/ethics-and-responsibility2025-10-08T13:48:26.34Z1.0https://www.us.argenx.com/ethics-and-responsibility/transparency-disclosure2025-08-01T14:37:37.652Z1.0https://www.us.argenx.com/externally-sponsored-research2025-12-23T20:43:33.79Z1.0https://www.us.argenx.com/regulations2025-10-13T12:45:50.972Z1.0https://www.us.argenx.com/case-studies2026-02-19T05:36:40.921Z1.0https://www.us.argenx.com/case-studies/argx-1182024-08-01T11:53:06.394Z1.0https://www.us.argenx.com/case-studies/efgartigimod2025-09-09T08:11:21.667Z1.0https://www.us.argenx.com/case-studies/argx-1152024-09-05T10:50:37.337Z1.0https://www.us.argenx.com/case-studies/iip-collaboration2026-02-19T05:34:25.496Z1.0https://www.us.argenx.com/patient-stories2024-08-01T11:29:41.003Z1.0https://www.us.argenx.com/patient-stories/eri-mg-patient-railroad-inspector-and-father-six2024-09-05T13:47:32.242Z1.0https://www.us.argenx.com/patient-stories/melissa-living-myositis-20192024-08-09T10:18:15.734Z1.0https://www.us.argenx.com/patient-stories/jamilah-cidp-patient-sharing-her-diagnosis-and-treatment-journey2024-07-31T09:36:11.335Z1.0https://www.us.argenx.com/search2024-07-25T10:34:41.259Z1.0https://www.us.argenx.com/community-guidelines2024-09-04T07:33:03.111Z1.0https://www.us.argenx.com/pipeline-publications-preview2024-09-17T09:57:37.691Z1.0https://www.us.argenx.com/the-story-of-the-llama2024-08-01T11:46:35.917Z1.0https://www.us.argenx.com/grants-and-sponsorships2024-08-01T06:00:36.847Z1.0https://www.us.argenx.com/information-on-pre-approval-access2024-08-01T06:28:07.812Z1.0https://www.us.argenx.com/instructions-for-use-sc-vial-with-vial-adapter2024-10-10T14:48:36.779Z1.0https://www.us.argenx.com/instructions-for-use-sc-vial-with-transfer-needle2025-02-18T17:27:50.179Z1.0https://www.us.argenx.com/events2025-10-21T16:53:22.023Z1.0https://www.us.argenx.com/pipeline-review2025-07-31T03:03:59.627Z1.0https://www.us.argenx.com/general-terms-and-conditions-of-purchasing-of-argenx2026-04-02T13:37:40.8Z1.0